retatrutide triple agonist glp-1 gip glucagon receptor Agonism Based Therapies for Obesity Retatrutide Obesity Triple Agonist Targeting

Possible relation to pancreatitis or pancreatic adenocarcinoma Another type of study of the exocrine pancreas has been to give GLP-1 mimetics or DPP-4 inhibitors to animals over a prolonged period of time and evaluate the pancreas for evidence of pancreatitis or precancerous lesions

The 18 to 24 months between now and retatrutide availability is not wasted time

Treatment requires specialist prescribing, regular monitoring for adverse effects including pancreatitis, and integration with lifestyle modifications

Lastly, the manufacturing focus needs to shift from volume-based planning to demand-based planning, especially with the planned increased indications and patient access